SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (540)3/24/1999 2:54:00 PM
From: scaram(o)ucheRespond to of 4974
 
Second- and third-tiers......

It feels, to me, very much like we're back to another "Amerindo-like" affair, where some fund/funds that doesn't/don't want to bail is/are being forced to do such (redemptions).

The slaughter goes on and on, and most biotech CEOs are helplessly sitting on their hands, looking at the desk in front of them, rather than turning to innovative M&A.

Egos and blinders. Get real, biotech CEOs!! Most of you are discounted. Put together a gaggle of the discounts, you lazy, greedy, egotistical, and *slow* leaders.



To: scaram(o)uche who wrote (540)3/24/1999 3:08:00 PM
From: scaram(o)ucheRead Replies (1) | Respond to of 4974
 
The blame for any further erosion in the lower tiers will lie squarely on the shoulders of the sector's CEOs. Until now, it's been largely out of their hands. However, the funding crisis has gone without innovative solutions for so long that it now reflects a lack of insight at the top.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News